For instance, Hodi et al. reported that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) demonstrated an objective response with durable remission for four years in one patient with ovarian cancer [153]. This evidence concerns the gene CSF2 and neoplasm.